Biolinerx.

BioLineRx overview BioLineRx is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML) and relapsed or refractory AML.

Biolinerx. Things To Know About Biolinerx.

BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) Six months ended June 30, 2022. 2023. in USD thousands. CASH FLOWS - OPERATING ACTIVITIESAbout BioLineRx. BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has ...15 thg 1, 2020 ... BioLineRx is currently in the midst of a Phase I/IIa clinical study testing intratumoral injections of AGI-134 in patients. What was the most ...BioLineRx said it plans for its drug to be ready for patients later this month. BioLineRx reported a net loss of $25 million in 2022 and a deficit of $330 million as of Dec. 31, 2022.

About BioLineRx BioLineRx Ltd. is a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases. The company is advancing a pipeline of investigational medicines for patients with multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors.BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide ...Dec 1, 2023 · BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic ...

BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma ...

2021 Annual Report 1.7 MB. 2020 Annual Report. 2020 Annual Report 899.8 KB. 2019 Annual Report. 2019 Annual Report 1.1 MB. 2018 Annual Report. 2018 Annual Report 1 MB. 2017 Annual Report. 2017 Annual Report 1 MB. About BioLineRx. BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.:םיפסונ םיטרפל ²£ ¨ ©² ¨ LifeSci Advisors, LLC +972-54-476-4945 [email protected] HSR Layout 761, 19th Main Rd, Garden Layout, Sector3, HSR Layout, Bengaluru, Karnataka 560102. Elucidata is an MLOps solutions provider for life sciences organizations. Our cloud-based platform Polly, delivers richly curated biomolecular data prepared for machine learning applications.

TEL AVIV, Israel, Nov. 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on …

Dec 1, 2023 · BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic ...

Whether you need us in one country or 100, our global network of premium facilities and local professionals are all connected in real time. Our neural network is fueled by in-depth regulatory knowledge, a rich database of patient populations, and a genuine understanding of the person behind the patient.Name of Applicant BioLineRx Ltd. Therapeutic Class Formulation(s) CXCR4 antagonist Lyophilized powder for reconstitution (73 mg per vial) Dosing Regimen . 1.25 mg/kg administered by subcutaneous injection 10-14 hours prior to initiation of apheresis; second dose of 1.25 mg/kg can be administered subcutaneously 10-14 hours prior to third apheresisMay 4, 2021 · BioLineRx will hold a conference call today, Tuesday, May 4, 2021 at 10:00 a.m. EDT. To access the conference call, please dial +1-866-860-9642 from the US or +972-3-918-0644 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior ... On December 15, BioLineRx announced the formation of an Immuno-Oncology Scientific Advisory Board (SAB) to provide insight and guidance on the Company's immuno-oncology activities. The SAB, which has provided valuable guidance to the AGI-134 development program, is comprised of recognized key opinion leaders in the fields of cancer …BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040 ...Financial Overview. At the end of Q3 2023, BLRX held $28.8 million in total current assets, of which $7.7 million was cash and equivalents, and $18.2 million was …Nov 20, 2023 · Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to ...

BioLineRx Ltd. (NASDAQ: BLRX) Class Period: February 23, 2021 – September 19, 2022 Lead Plaintiff Deadline: March 6, 2023. The complaint filed in this class action alleges that Defendants made ...BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business ...Nov 20, 2023 · BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) December 31, September 30, 2022. 2023. in USD thousands. Assets Koji Sasaki, Hagop M. Kantarjian, Bachar Samra, Nicholas J. Short, Joseph D. Khoury, Rashmi Kanagal-Shamanna, Marina Y Konopleva, Nitin Jain, Courtney D. DiNardo, Rita Khouri, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Nicole Tippett, Rebecca Garris, Victoria Jeanis, Naval G. Daver, Philip A. Thompson, Musa …Information on stock, financials, earnings, subsidiaries, investors, and executives for BioLineRx. Use the PitchBook Platform to explore the full profile.1 Wall Street analysts have issued twelve-month price objectives for BioLineRx's stock. Their BLRX share price targets range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 1,281.6% from the stock's current price.BioLineRx submitted a 505(b)(1) application to obtain marketing approval of Aphexda (motixafortide). Aphexda is a hematopoietic stem cell mobilizer proposed in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with …

Nov 4, 2022 · TEL AVIV, Israel, Nov. 4, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"). The letter notifies the Company that it is not in compliance with the minimum bid price ...

BioLineRx Ltd. (BLRX) is a biotechnology company that develops and sells products for cancer and other diseases. The stock price, news, quote and history of BLRX are shown on Yahoo Finance. See the latest performance outlook, earnings, dividends, research reports and more.BioLineRx is preparing the NDA Motixafortide with a planned submission in Q3-2022. Motixafortide is also being evaluated in a phase 2 clinical studies, in US and China, as treatment for pancreatic cancer in combination with immune therapy and chemotherapy. www.biokine.com;Oct 13, 2021 · TEL AVIV, Israel, Oct. 13, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating ... BioLineRx will hold a conference call today, Tuesday, May 4, 2021 at 10:00 a.m. EDT. To access the conference call, please dial +1-866-860-9642 from the US or +972-3-918-0644 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior ...These data can be requested via email to [email protected], and will be made available to requesting parties through the Egnyte system following approval. This request and availability mechanism ...BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx's views only as of the date ofSorani:Biolinerx Ltd.: Current Employment, Current equity holder in publicly-traded company. Gliko Kabir:BioLineRx Ltd.: Current Employment, Current equity holder in publicly-traded company. Goldstein:BioLineRx Ltd.: Current Employment, Current equity holder in publicly-traded company. Lustig:BioLineRx Ltd.: Current Employment, Current …Israel Headquarters. Modi’in Technology Park 2 HaMa’ayan Street Modi’in 7177871, IsraelAbout BioLineRx BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first ...Jun 28, 2022 · About BioLineRx. BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has reported ...

28 thg 9, 2023 ... TEL AVIV, Israel, September 28, 2023 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing ...

Sep 13, 2023 · BioLineRx said it plans for its drug to be ready for patients later this month. BioLineRx reported a net loss of $25 million in 2022 and a deficit of $330 million as of Dec. 31, 2022.

BioLineRx Ltd. (BLRX) is a biotechnology company that develops and sells products for cancer and other diseases. The stock price, news, quote and history of BLRX are shown on Yahoo Finance. See the latest performance outlook, earnings, dividends, research reports and more. BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003. BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development of therapeutics, primarily in pre-commercialization and clinical stages, with a focus on the field of oncology.About BioLineRx BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.Sorani:Biolinerx Ltd.: Current Employment, Current equity holder in publicly-traded company. Gliko Kabir:BioLineRx Ltd.: Current Employment, Current equity holder in publicly-traded company. Goldstein:BioLineRx Ltd.: Current Employment, Current equity holder in publicly-traded company. Lustig:BioLineRx Ltd.: Current Employment, Current …BioLineRx said it plans for its drug to be ready for patients later this month. BioLineRx reported a net loss of $25 million in 2022 and a deficit of $330 million as of Dec. 31, 2022.Feb 25. BioLineRX. 2018-02-25. BioLineRX. Facebook · Twitter · Tumblr · Pinterest · Google+ · LinkedIn · E-Mail. Comments are closed. Categories.About BioLineRx. BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases.BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has reported positive results from a ...BioLineRx Ltd. (BLRX) is a biotechnology company that develops and sells products for cancer and other diseases. The stock price, news, quote and history of BLRX are shown on Yahoo Finance. See the latest performance outlook, earnings, dividends, research reports and more.BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that pilot phase data from ...

972-08-6429101. E-Mail: [email protected]. Authorization Status: Recognized. Site: https://www.biolinerx.com. First authorization date: 4/03/2010. Valid until ...OPT. Opthea Ltd. 1.96. UNCH. UNCH. Get BioLine RX Ltd (BLRX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.BioLineRX office in Har Hotzvim Technology Park, Jerusalem. BioLineRx ( Hebrew: ביוליין אר אקס ), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange .Jul 17, 2023 · TEL AVIV, Israel, July 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers ... Instagram:https://instagram. ttoo newsbest overseas forex brokers us residentsstock wmtday trader computer setup BioLineRx Ltd. (NASDAQ: BLRX) Class Period: February 23, 2021 – September 19, 2022 Lead Plaintiff Deadline: March 6, 2023. The complaint filed in this class action alleges that Defendants made ... battery recycling company stocksvalue of 1921 silver dollars Sep 13, 2023 · BioLineRx said it plans for its drug to be ready for patients later this month. BioLineRx reported a net loss of $25 million in 2022 and a deficit of $330 million as of Dec. 31, 2022. nasdaq ww compare 28 thg 9, 2023 ... TEL AVIV, Israel, September 28, 2023 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing ...Sep 28, 2023 · Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to ...